Praxis Precision Medicines, Inc.NASDAQ: PRAX

Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor

· Issued by Praxis Precision Medicines, Inc.

Patients treated with ulixacaltamide in the parallel-group study (Study 1) showed a mean improvement from baseline in the Modified Activities of Daily Living 11 at Week 8, the pre-specified primary endpoint, of 4.3 points (p

Praxis Precision Medicines, Inc. on 6ix

In the deck

Story so far

Earlier from Praxis Precision Medicines

Later from Praxis Precision Medicines

All Praxis Precision Medicines news releases